HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lack of apparent short-term benefit of photodynamic therapy in bilateral, acquired, parafoveal telangiectasis without subretinal neovascularization.

AbstractPURPOSE:
To analyze the results of photodynamic therapy (PDT) in bilateral acquired parafoveal telangiectasis.
DESIGN:
Interventional cases report.
METHOD:
Retrospective analysis of visual acuity measured with ETDRS charts and of fluorescein angiography findings for two women in whom the eye with lesser visual acuity was treated by PDT for bilateral acquired parafoveal telangiectasis without subretinal neovascularization.
RESULTS:
Initial visual acuity of the treated eye was 20/63 in both patients and did not change significantly for 3 to 6 months after one session of PDT. Fluorescein angiography in both cases and optical coherence tomography in one case also appeared unchanged. No adverse effect has been observed.
CONCLUSIONS:
Photodynamic therapy was not beneficial for the outcome of these patients with bilateral acquired telangiectasis, because it improved neither their visual acuity nor their macular edema.
AuthorsGhislaine Ducos De Lahitte, Salomon Y Cohen, Alain Gaudric
JournalAmerican journal of ophthalmology (Am J Ophthalmol) Vol. 138 Issue 5 Pg. 892-4 (Nov 2004) ISSN: 0002-9394 [Print] United States
PMID15531343 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Photosensitizing Agents
  • Porphyrins
  • Verteporfin
Topics
  • Adult
  • Female
  • Fluorescein Angiography
  • Humans
  • Middle Aged
  • Photochemotherapy
  • Photosensitizing Agents (therapeutic use)
  • Porphyrins (therapeutic use)
  • Retinal Diseases (diagnosis, drug therapy)
  • Retinal Neovascularization (drug therapy)
  • Retinal Vessels (drug effects, pathology)
  • Retrospective Studies
  • Telangiectasis (diagnosis, drug therapy)
  • Tomography, Optical Coherence
  • Treatment Outcome
  • Verteporfin
  • Visual Acuity

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: